16+
Major trials tracked
An oral GLP-1 candidate against an injectable GLP-1 standard
Orforglipron vs semaglutide: trial pipelines compared
A side-by-side view of the orforglipron and semaglutide clinical trial pipelines, built from live ClinicalTrials.gov data and refreshed daily. ClinicalTrials.gov lists 16+ phase 2–4 trials for orforglipron and 16+ for semaglutide. Add up to three more drugs to widen the comparison.
orforglipron (16) vs semaglutide (16)19 active2014–2033
orforglipronsemaglutide
'14
'16
'18
'20
'22
'24
'26
'28
'30
'32
orforglipron
ACHIEVE-4P3
ATTAIN-1P3
ATTAIN-2P3
ACHIEVE-1P3
ACHIEVE-3P3
ACHIEVE-5P3
ACHIEVE-2P3
ATTAIN-OSAP3
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)P3
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 DiabetesP3
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related ComorbidityP3
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 DiabetesP3
ATTAIN-OA PAINP3
RESTRAIN-SUIP3
ATTAIN-PADP3
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)P3
semaglutide
SUSTAIN™ 4P3
SUSTAIN™P3
SUSTAIN 7P3
STEP 3P3
STEP 6P3
STEP7P3
ASCEND PLUSP4
A Phase III Study Comparing the Weight Loss Effects of Semaglutide Injection and Wegovy®P3
A Study of HRS9531 Versus Semaglutide Once Weekly as Add-on Therapy to Metformin Monotherapy or in Combination With SGLT2 Inhibitors in Participants With Type 2 DiabetesP3
A Study of BGM0504 in Participants with Type 2 DiabetesP3
A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney DiseaseP2
Efficacy and Safety of Semaglutide Injection Vs WEGOVY® in Chinese Obese PatientsP3
A Clinical Study Comparing Semaglutide Injection and Wegovy® for Weight Management in Obese SubjectsP3
Phase III Clinical Study on the Efficacy and Safety of Semaglutide and Ozempic® in Patients With Type 2 DiabetesP3
Phase III Clinical Study Comparing the Efficacy and Safety of GZR18 Injection and Semaglutide (Wegovy®) in Adult Obese or Overweight SubjectsP3
AMAZE 8P3
Upcoming readouts
14 ahead · 2 drugs
Select a trial to load its full ClinicalTrials.gov record.
Head to head
Registered phase 2–4 trial activity for each drug, computed from live ClinicalTrials.gov data.
orforglipronGLP-1 & incretin therapies
16
Phase 3 trials
4
Actively recruiting
Nov 2026
Next phase 3 readout
semaglutide (Ozempic / Wegovy)GLP-1 & incretin therapies
16+
Major trials tracked
14
Phase 3 trials
4
Actively recruiting
Jun 2027
Next phase 3 readout
Key trials across both drugs
Top 16 registered phase 2–4 trials across orforglipron and semaglutide, ordered by phase and status. Trial names open the full ComplyRx trial page; NCT ids link to ClinicalTrials.gov.
Track orforglipron and semaglutide with ComplyRx
Get an alert when a trial changes status, moves its completion date, or a new trial registers in scope. Checked nightly against ClinicalTrials.gov.
Individual pipelines and other comparisons
FAQ
- How do the orforglipron and semaglutide clinical pipelines compare?
- ClinicalTrials.gov currently lists 16+ phase 2–4 trials for orforglipron and 16+ for semaglutide. The timeline above plots both side by side and refreshes daily.
- Where does this data come from?
- All trial data is sourced from ClinicalTrials.gov (CTGov) and refreshed on this page daily. ComplyRx does not add efficacy or superiority claims; the comparison shows registered trial activity only.
- Can I add more drugs to the comparison?
- Yes. The tool above compares up to five drugs on one timeline, with PNG and PDF export. Add any competitor in the search box.